Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
Dalbavancin, a long-acting lipoglycopeptide, was evaluated against 81,673 isolates of staphylococci, enterococci, and streptococci collected from 33 countries during worldwide resistance surveillance (2002 to 2007). Regardless of susceptibility to oxacillin, comparable potencies for dalbavancin against Staphylococcus aureus and coagulase-negative staphylococci from all countries were noted (MIC(90), 0.06 to 0.12 microg/ml). Vancomycin-susceptible Enterococcus spp. had dalbavancin MIC(90)s comparable to those for staphylococci, whereas vancomycin-resistant strains were more resistant (MIC(50), >4 microg/ml). beta-Hemolytic and viridians group streptococci were very susceptible to dalbavancin (MIC(90), <or=0.03 microg/ml). Overall, dalbavancin was >or=16-fold more active than vancomycin against the monitored gram-positive species.
Biedenbach
Douglas J
DJ
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA. douglas-biedenbach@jmilabs.com
Bell
Jan M
JM
Sader
Helio S
HS
Turnidge
John D
JD
Jones
Ronald N
RN
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001208:Asia; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D005060:Europe; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification*; D006801:Humans; D007843:Latin America; D008826:Microbial Sensitivity Tests; D009656:North America; D010140:Pacific Ocean; D011786:Quality Control; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin; C469289:dalbavancin